Phorm bags £15m to fund rollout of ad targeting system
The company has sold more than three million shares to institutional investors at £4.50 per share, which is cheaper then the stock’s current value on the AIM market.
Phorm CEO Kent Ertugrul said: “I am pleased that the financial community has demonstrated its support for Phorm with a substantially over-subscribed offering… With the addition of these new funds, we are well positioned to deliver strong growth as we engage with ISPs across the globe with a view to deployment in multiple markets.”
The firm’s behavioural tracking software uses deep packet inspection technology to track the websites a user visits in order to match them with relevant advertising.
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments